192181-49-0

Upstream product

• 99-55-8 2-methyl-5-nitroaniline 
• 121-86-8 2-chloro-4-nitrotoluene 
• 100-67-4 potassium phenolate 
• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 108-95-2 phenol 

Downstream Products

• 27231-26-1 3-amino-9H-xanthen-9-one 
• 62350-74-7 phenyl 2-hydroxy-4-nitrobenzoate 
• 619-19-2 2-hydroxy-4-nitrobenzoic acid 
• 860699-15-6 4-nitro-2-(4-nitro-phenoxy)-benzoic acid 
• 734524-98-2 4-amino-2-phenoxy-benzoic acid 

Relevant academic research and scientific papers

5-[Aryloxypyridyl (or nitrophenyl)]-4H-1,2,4-triazoles as novel flexible benzodiazepine analogues: Synthesis, receptor binding affinity and lipophilicity-dependent anti-seizure onset of action

A new series of 5-(2-aryloxy-4-nitrophenyl)-4H-1,2,4-triazoles and 5-(2-aryloxy-3-pyridyl)-4H-1,2,4-triazoles, possessing C-3 thio or alkylthio substituents, was synthesized and evaluated for their benzodiazepine receptor affinity and anti-seizure activit

Carboxyl radical-assisted 1,5-aryl migration through Smiles rearrangement

We report herein, a silver(i)-catalyzed Smiles rearrangement of 2-aryloxy- or 2-(arylthio)benzoic acids to provide aryl-2-hydroxybenzoate or aryl-2-mercaptobenzoate dimer, respectively, through 1,5-aryl migration from oxygen or sulfur to carboxylate oxygen. Mechanistically, the aryl ether moiety undergoes an intramolecular ipso attack by the carboxyl radical followed by a C-O or C-S bond cleavage. Aryl-2-mercaptobenzoates undergo oxidative dimerization through a thiol moiety in situ.

Fab I inhibitors

Compounds of formula (I) and (II) are disclosed wherein, R1, R2, R3, R4, X, A, B, D and Q are as disclosed in the specification, and the compounds are FabI inhibitors useful in the treatment of bacterial infecti